Media Contacts
photo:Tulchan  Communications
Tulchan Communications
Tom Buchanan
020 7353 4200
Share this release
Share on: Twitter
Share on: Facebook
Share on: LinkedIn
Latest news
York,
29
April
2015

DermaPure™ US Clinical data to be presented at major US Wound Care Conference

Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, announces its plans for the Symposium for Advanced Wound Care (SAWC) Spring meeting being held in San Antonio this week.

Now in its 28th year, SAWC is one of the most respected names in wound care education and brings together over 2000 industry professionals each year from across the world.

At a breakfast symposium sponsored by Tissue Regenix, we will demonstrate to attendees the outstanding results of a case series of 10 US patients treated with DermaPure™. The patients involved in the study had multiple types of wounds with an average size of 12.9cm2 and saw 100% healing in an average time of 6.5 weeks with 1.1 applications.

The presenters are Patti Gary, RN, CWCN, Vice President Clinical Affairs, Tissue Regenix, San Antonio, TX; Dr. Ardeshir Bayat, University of Manchester, Manchester Institute of Biotechnology; C. Jake Lambert, Jr. MD, Bond Clinic, Winter Haven, FL

A poster presentation of the results will also be shown at the meeting.

Website: http://www.sawc.net/spring/

Antony Odell, CEO of Tissue Regenix
“SAWC is a key date in the US wound care professional’s calendar and we are proud to be sharing the positive US clinical experiences with the attendees. DermaPure™ continues to demonstrate exceptional clinical results in many very difficult wounds that other types of approach have failed to heal and provides the potential for dramatic improvements in the clinical outcome of 6.5 million US patients per year.”
Antony Odell, CEO of Tissue Regenix
About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®’) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- ‘Tissue Regenix Wound Care Inc.’, as part of its commercialisation strategy for its dCELL® technology platform.